At a glance
• BPC-157 and TB-500 are two different peptides studied for tissue repair and often mentioned together. • Their combination has been studied very little: one small preclinical study in 2026 and one retrospective series of 4 people without a control group. • There is no controlled study of the combination in humans.
Two different molecules
• What it is — BPC-157: synthetic 15-amino-acid peptide, a fragment of a gastric juice protein · TB-500: synthetic 7-amino-acid fragment of thymosin β4 (Ac-LKKTETQ), according to the FDA • Main mechanisms studied — BPC-157: cell migration via FAK–paxillin, VEGFR2–Akt–eNOS signalling and nitric oxide · TB-500: actin binding and cell motility, via the LKKTETQ motif • Studies in humans — BPC-157: three small pilot studies without a control group · TB-500: none; clinical studies exist only for full-length thymosin β4 • WADA 2026 — BPC-157: category S0 · TB-500: category S2.3 For details on each peptide, see our articles on BPC-157 and on TB-500 and thymosin β4.
Why they are mentioned together
There are three reasons: 1. A shared research field. Both are studied in models of tendon, muscle and skin healing, and reviews place them in the same group of "healing peptides" (Rahman 2026). 2. Different routes to similar outcomes. BPC-157 has been linked to VEGFR2 signalling and nitric oxide (Hsieh 2017) and to FAK–paxillin activation (Chang 2011). Thymosin β4 has been linked to actin (Huff 2001) and to the PINCH/ILK complex (Bock-Marquette 2004). Both routes reach the Akt protein, from a different point. This leads some researchers to hypothesise that they may complement each other. The hypothesis has not been confirmed. 3. The market. The two peptides are often sold as a ready-made blend, something the FDA also notes in its 2026 briefing document.
What has been studied about the combination
The only controlled study (Biçer 2026). In an Achilles tendon injury model, an independent research group compared BPC-157, TB-500 and their combination with a control group, over 4 weeks. • TB-500 showed a statistically significantly higher load to failure than the control group. • BPC-157 showed numerical, not statistically significant, improvements. • A group with the combination of the two was also examined. The researchers themselves describe the study as exploratory: it was small (8 per group), with a single time point, and did not state the exact composition of the TB-500 material. They hypothesised that the two substances may converge on shared pathways and noted that this needs further confirmation. A study this small is not enough for conclusions about the combination. In humans. In a retrospective series of patients with knee pain (Lee 2021), 4 people received BPC-157 together with "thymosin β4". The study had no control group or validated measurement tools, and does not specify which form of thymosin was used. It allows no conclusion about the combination.
What we do not know yet
• What the combination offers. The data are too few to answer this; larger controlled studies are needed. • Whether the mechanisms complement or overlap each other. For now this is only a hypothesis. • Safety of the combination: no data exist. For each substance separately, the FDA notes a lack of human safety data. • Material identity: different forms are sold under the name TB-500. In any research, the composition must be documented per batch with a laboratory analysis (COA).
Frequently asked questions
Has the combination of BPC-157 and TB-500 been studied? Very little: in one small 2026 preclinical study and in one retrospective series of 4 people without a control group. The data are not enough for conclusions. What is the difference between BPC-157 and TB-500? They are different molecules: BPC-157 has 15 amino acids and is studied mainly for cell migration and nitric oxide, TB-500 has 7 amino acids and relates to actin. Are they banned in sport? Yes. WADA lists BPC-157 in category S0 and thymosin β4 with its derivatives, such as TB-500, in category S2.3. Where are they available for research use in Greece? Avenor supplies BPC-157 + TB-500 strictly for laboratory research, with batch documentation (COA).
Sources
1. Biçer O et al. Jt Dis Relat Surg 2026. PMID 42542926 2. Lee E, Padgett B. Altern Ther Health Med 2021. PMID 34324435 3. Rahman OF et al. JAAOS Global Research & Reviews 2026. PMID 41490200 4. Hsieh MJ et al. J Mol Med 2017. PMID 27847966 5. Chang CH et al. J Appl Physiol 2011. PMID 21030672 6. Huff T et al. Int J Biochem Cell Biol 2001. PMID 11311852 7. Bock-Marquette I et al. Nature 2004. PMID 15565145 8. FDA, Briefing Documents PCAC, BPC-157 and TB-500, 2026 9. WADA, Prohibited List 2026
RUO note
This article is an informational overview of published research. It is not medical advice and gives no directions for use, amounts or protocols. Avenor products are supplied strictly for laboratory research and not for human or veterinary use.